Latest Research And Development News

Zoono Group has landed its first commercial orders from three new packaging partners, marking a key milestone in its fresh food shelf-life extension strategy. The company reports NZ$551,000 cash on hand as it navigates growth and funding options.

Enlitic, Inc. reported its strongest quarter yet with record contract wins totalling A$4.3 million, alongside a strategic capital raise and new cost-saving measures to fuel growth.

Amplia Therapeutics reports encouraging clinical progress for its pancreatic cancer drug narmafotinib, with a 35% confirmed response rate in the ACCENT trial and FDA support for dose optimisation. The company also uplisted to the US OTCQB market and secured a key patent extending protection to 2040.

NeuroScientific Biopharmaceuticals has reported promising initial clinical responses from its StemSmart™ Special Access Program treating Fistulising Crohn’s Disease, while preparing for a pivotal Phase 2 trial in 2026.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Agrimin Limited has ceased capital allocation to its Mackay Potash Project following a strategic review, while advancing exploration efforts in the promising West Arunta region.

Ardea Resources has made disciplined progress on its Kalgoorlie Nickel Project’s Definitive Feasibility Study, supported by renewed Major Project Status and full funding from a Japanese consortium. Completion is on track for mid-2026 amid robust resource updates and strategic partnerships.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.

Parkway Corporate Limited reported steady revenues of $3.64 million for Q2 FY26 and breakeven EBITDA, while progressing its flagship Queensland Brine Management Complex project with a secured site and lodged development application.

Argent BioPharma has restructured its acquisition of AusCann assets to sharpen its clinical focus and secured a substantial A$11 million financing facility, positioning itself for growth in 2026.

First Graphene Limited has reported a landmark quarter with a 156% surge in customer cash receipts and a major industrial-scale production of graphene-enhanced cement, signalling a pivotal step in commercialising graphene across multiple sectors.

Rent.com.au has reported its strongest quarter yet, breaking the $1 million revenue mark with a significant surge in recurring revenue driven by its RentPay and RentBond products.